Pharma: Other News To Note
Friday, September 28, 2012
Forest Laboratories Inc., of New York, and Pierre Fabre Laboratories, of Castres, France, said Forest submitted a new drug application for levomilnacipran, a serotonin norephinephrine reuptake inhibitor, for the treatment of major depressive disorder in adults.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.